E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Search
- Page Path
- HOME > Search
Review Article
- Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma
- Yuri Cho, Jimin Han, Won Kim
- J Liver Cancer. 2019;19(1):1-11. Published online March 31, 2019
- DOI: https://doi.org/10.17998/jlc.19.1.1
- 5,132 Views
- 144 Downloads
- 5 Citations
-
Abstract
PDF - Systemic target therapeutic drugs, such as sorafenib, lenvatinib, or regorafenib are the only drugs that are known to be effective against advanced hepatocellular carcinoma (HCC). However, these agents show a limited efficacy in killing residual tumors. Immunotherapy is an alternative approach to this treatment and has been used to successfully treat different cancers, including HCC. HCC is an inflammation-induced cancer and represents a very interesting target for immunotherapeutics. Immunotherapies aim to reverse the immune tolerance and suppression found in tumor microenvironments and include approaches, such as adoptive cell therapy, immune checkpoint inhibition, and cancer vaccination. Adoptive cell therapy uses autologous natural killer or cytokine-induced killer cells by cultivating them ex vivo and subsequently reinfusing them into the patient. Immune checkpoint inhibitors reactivate tumorspecific T cells by suppressing checkpoint-mediated inhibitory signaling. Cancer vaccination induces a tumor-specific immune response by activating effector T lymphocytes. A wide range of potential immunotherapy-related adverse events occur; therefore, a multidisciplinary collaborative management is required across the clinical spectrum. This review summarizes the current status of immunotherapy for HCC and provides a perspective on its future applications.
-
Citations
Citations to this article as recorded by
- Exploring the potential of Toxoplasma gondii in drug development and as a delivery system
Chanjin Yoon, Yu Seong Ham, Woo Jin Gil, Chul-Su Yang
Experimental & Molecular Medicine.2024; 56(2): 289. CrossRef - Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
Jeayeon Park, Yun Bin Lee, Yunmi Ko, Youngsu Park, Hyunjae Shin, Moon Haeng Hur, Min Kyung Park, Dae-Won Lee, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Tae-Yong Kim, Yoon Jun Kim, Tae-You Kim, Jung-Hwan Yoon
Journal of Liver Cancer.2024; 24(1): 81. CrossRef - Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities
Disha D. Shah, Bhavarth P. Dave, Parv A. Patel, Mehul R. Chorawala, Vishvas N. Patel, Palak A. Shah, Manish P. Patel
Medical Oncology.2023;[Epub] CrossRef - Differences between exhausted CD8+ T cells in hepatocellular carcinoma patients with and without uremia
Chen Xiaohong, Zou Jianzhou, Shen Bo, Lv Wenlv, Cao Xuesen, Xiang Fangfang
Canadian Journal of Physiology and Pharmacology.2021; 99(4): 395. CrossRef - Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
Jaewoong Kim, Jin Won Chang, Jun Yong Park
Journal of Liver Cancer.2020; 20(1): 72. CrossRef
- Exploring the potential of Toxoplasma gondii in drug development and as a delivery system
First
Prev
Follow JLC on Twitter